Teligent, Inc. (TLGT) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Teligent, Inc. (TLGT) Healthcare & Pipeline Overview

Teligent, Inc. is a specialty generic pharmaceutical company marketing injectable and topical products in the US and Canada. It differentiates itself through focus on complex dosage forms and contract manufacturing, operating in a competitive generic drug market with ongoing regulatory and pipeline development challenges.

What Is the Investment Thesis for TLGT?

Teligent, Inc. presents a challenging investment case given its negative profit and gross margins of -269.3% and -8.2%, respectively. The company operates in the competitive generic pharmaceutical market, facing pricing pressures and regulatory hurdles. A potential value driver lies in its pipeline of 20 ANDAs filed with the FDA as of December 2018, which, if approved, could expand its product offerings and revenue streams. However, the company's ability to navigate the complex regulatory landscape and achieve profitability remains uncertain. Investors should closely monitor the progress of its ANDA approvals and its efforts to improve operational efficiency.

Based on FMP financials and quantitative analysis

TLGT Key Highlights

Teligent operates in the specialty generic pharmaceutical sector, focusing on topical and injectable products.

• The company markets products in the United States and Canada.
• As of December 31, 2018, Teligent had 20 Abbreviated New Drug Applications (ANDAs) filed with the FDA.
• The company's profit margin is -269.3%.
• The company's gross margin is -8.2%.

Who Are TLGT's Competitors?

TLGT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TLGT's Key Strengths?

Focus on specialty generic pharmaceuticals.

• Presence in both US and Canadian markets.
• Pipeline of ANDAs filed with the FDA.
• Offers contract manufacturing services.

What Are TLGT's Weaknesses?

Negative profit margin.

• Negative gross margin.
• High dependence on regulatory approvals.
• Intense competition in the generic drug market.

What Could Drive TLGT Stock Higher?

TLGT catalyst: FDA approval decisions on pending ANDA applications (timeline varies, but expect updates within 12-24 months per application).

• Efforts to improve operational efficiency and reduce costs.
• Expansion of contract manufacturing services to new clients.

What Are the Key Risks for TLGT?

Delays or rejections of ANDA applications by the FDA.

• Pricing pressures in the generic drug market impacting profit margins.
• Increased competition from other generic pharmaceutical manufacturers.
• Changes in healthcare regulations affecting the generic drug industry.
• Negative profit and gross margins indicating financial instability.

What Are the Growth Opportunities for TLGT?

• Expansion of Injectable Product Line: Teligent can capitalize on the growing demand for generic injectable drugs. The global injectable drug market is projected to reach $700 billion by 2028, driven by advancements in drug delivery systems and the increasing prevalence of chronic diseases. By successfully launching new generic injectable products, Teligent can increase its market share and revenue. This strategy requires efficient manufacturing processes and a strong distribution network.
• FDA ANDA Approvals: Teligent's pipeline of 20 ANDAs filed with the FDA represents a significant growth opportunity. Successful approval and commercialization of these ANDAs would expand the company's product portfolio and generate new revenue streams. The generic drug approval process typically takes 1-3 years, so approvals could be expected between 2026 and 2028. The key is to prioritize ANDAs with high market potential and navigate the regulatory process effectively.
• Contract Manufacturing and Formulation Services: Teligent can leverage its manufacturing capabilities to expand its contract manufacturing and formulation services business. The global pharmaceutical contract manufacturing market is expected to reach $200 billion by 2027, driven by pharmaceutical companies outsourcing manufacturing to reduce costs and improve efficiency. By offering competitive pricing and high-quality services, Teligent can attract new clients and diversify its revenue base.
• Geographic Expansion into New Markets: Teligent currently markets its products in the United States and Canada. Expanding into new geographic markets, such as Europe and Asia, could significantly increase its revenue potential. These markets offer large patient populations and growing demand for generic drugs. However, geographic expansion requires careful planning and investment in regulatory compliance and distribution infrastructure.
• Focus on Complex Dosage Forms: Teligent's focus on developing and manufacturing generic pharmaceutical products in complex dosage forms, such as ophthalmic products, presents a growth opportunity. Complex dosage forms often have higher barriers to entry, reducing competition and increasing profitability. By investing in research and development capabilities, Teligent can develop and commercialize new complex generic products and capture a larger share of the market.

What Are TLGT's Competitive Advantages?

• Specialized in complex dosage forms like injectables and ophthalmics, creating higher barriers to entry.
• Contract manufacturing services provide a diversified revenue stream.
• Pipeline of ANDAs represents potential future product approvals and revenue.
• Established presence in the US and Canadian generic drug markets.

What Does TLGT Do?

Teligent, Inc., formerly Igi Laboratories Inc, was established to focus on the development, manufacturing, and marketing of generic pharmaceutical products. The company operates primarily in the specialty generic pharmaceutical sector, concentrating on topical and injectable products. Teligent markets and sells generic injectable pharmaceutical products in both the United States and Canada. As of December 31, 2018, Teligent marketed 35 generic topical pharmaceutical products and four branded generic pharmaceutical products in the United States. In addition to its own branded generics, Teligent provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic industries. The company focuses on developing, manufacturing, and marketing a portfolio of generic pharmaceutical products under its own label in topical, injectable, complex, and ophthalmic dosage forms. Teligent also manages its contract manufacturing and formulation services business. The company's pipeline included 20 Abbreviated New Drug Applications (ANDAs) filed with the United States Food and Drug Administration (FDA) for additional pharmaceutical products, as of December 31, 2018.

What Products and Services Does TLGT Offer?

• Develops generic pharmaceutical products.
• Manufactures generic pharmaceutical products.
• Markets generic injectable pharmaceutical products in the United States and Canada.
• Markets generic topical pharmaceutical products in the United States.
• Provides development and formulation services to pharmaceutical companies.
• Provides manufacturing services to pharmaceutical companies.
• Focuses on topical, injectable, complex, and ophthalmic dosage forms.

How Does TLGT Make Money?

• Develops and manufactures generic pharmaceutical products.
• Markets and sells generic products under its own label.
• Provides contract manufacturing and formulation services to other companies.
• Generates revenue through product sales and service fees.

What Industry Does TLGT Operate In?

Teligent, Inc. operates within the specialty generic pharmaceutical industry, a segment characterized by intense competition and pricing pressures. Companies in this sector focus on developing and marketing generic versions of off-patent drugs. The industry is heavily regulated, requiring companies to navigate complex approval processes with agencies like the FDA. Market trends include a growing demand for affordable healthcare, driving the need for generic drugs. Teligent competes with other generic drug manufacturers, facing challenges in maintaining profitability and securing market share. The company's success depends on its ability to efficiently develop and commercialize new generic products.

Who Are TLGT's Key Customers?

• Pharmacies
• Hospitals
• Wholesalers
• Pharmaceutical companies (for contract manufacturing)

How Teligent, Inc. Is Valued

Relative to its peer group, TLGT's quantitative score of 35/100 is below the peer average of 59/100.

Company Profile

Teligent, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Buena, US. The company is led by CEO Timothy Sawyer. TLGT has traded publicly since 1981.

Return on equity for Teligent, Inc. stands at 211.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 1.92 indicates the company holds enough short-term assets to cover its near-term obligations.

TLGT Financials

TLGT Latest News

No recent news available for TLGT.

TLGT Analyst Consensus

TLGT MoonshotScore

What Investors Ask About Teligent, Inc. (TLGT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources